(Press-News.org) A drug candidate developed by researchers at the University of Tennessee Health Science Center for advanced metastatic castration-resistant prostate cancer is now in its first clinical trial.
Ramesh Narayanan, PhD, deputy director of the Center for Cancer Research and the Muirhead Endowed Professor in the College of Medicine at UTHSC, and Duane Miller, PhD, Professor Emeritus in the Department of Pharmaceutical Sciences at UTHSC, have worked for more than a decade on therapies involving the hormone receptors that influence cancer progression. Their drug candidate, a molecule designed as a treatment for advanced metastatic prostate cancer, is now in its first clinical trial.
"This is a very, very rare occurrence,” Dr. Narayanan said. “If you take all the academic researchers in the United States, probably only an insignificant percent would have the luxury or the privilege of taking a drug all the way from concept to clinical trial."
Biopharmaceutical company Oncternal Therapeutics, Inc., holds the license for the drug candidate, an androgen (male hormone) receptor inhibitor dubbed ONCT-534, developed at UTHSC by Drs. Narayanan and Miller. On October 5, the company announced the first patient had received ONCT-534. On October 26, Oncternal disclosed that the FDA granted fast-track designation for ONCT-534, which could potentially accelerate the clinical development process.
“If you look at prostate cancer, most of the time it occurs in patients over 40, and about 60% are over 60,” Dr. Miller said. “And it turns out that black men have a higher incidence, like 70% of the diagnoses, than white men.”
"We felt that there is a significant need for this patient population," Dr. Narayanan said.
Existing treatments for prostate cancer target androgens, extending survival for most patients. However, roughly 30 percent of tumors do not respond, and patients who initially respond often develop resistance.
“Enzalutamide is normally the drug that's chosen to give to men," Dr. Miller explained. “With time, it just doesn't work, and we tried to figure out what's going on there.”
One of the primary reasons for treatment failure or relapse is a mutation of the receptor protein for androgens. Enzalutamide works on one area of the receptor.
ONCT-534 is a dual-action androgen receptor inhibitor that has shown activity in prostate cancer models against unmutated and mutated androgen receptors. The research on the drug candidate has been funded by the National Cancer Institute, Oncternal, and GTx Inc., the company that became Oncternal.
"It looks like our drug is a very strong candidate for treating these patients who have relapsed from current treatment options," Dr. Narayanan says. "It may potentially have the possibility to extend the survival.”
Drs. Narayanan and Miller are collaborators on several projects, including the preclinical development of a molecule to treat Kennedy’s Disease, a rare progressive neurodegenerative disease in younger men. Dr. Miller and his team are responsible for the chemistry, designing the molecules and testing and refining the structure. Dr. Narayanan and his team do the pharmacological testing to see how they perform in the lab.
As the licensee for ONCT-534, Oncternal has handled the lengthy process leading to FDA approval for clinical trials that will test safety, efficacy, and finally, how it compares against current standard treatments. Passing all three hurdles could advance a drug to market someday.
The mission of the University of Tennessee Health Science Center is transforming lives through collaborative and inclusive education, research, scholarship, clinical care, and public service. With six colleges – Dentistry, Graduate Health Sciences, Health Professions, Medicine, Nursing, and Pharmacy – at its main campus in Memphis, in addition to educational and clinical campuses at major hospitals in Memphis, Knoxville, Chattanooga, and Nashville, and sites across the state, UTHSC strives to fulfill its vision: Healthy Tennesseans. Thriving Communities. For more information, visit www.uthsc.edu. You can find the University of Tennessee Health Science Center on Facebook, Instagram, LinkedIn, X, and YouTube.
END
Prostate cancer drug candidate developed at University of Tennessee Health Science Center goes to first clinical trial
2023-11-06
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Model suggests that mammalian sperm cells have two modes of swimming
2023-11-06
A new mathematical model predicts that mammalian sperm cells have two distinct swimming modes. This prediction opens new questions about potential connections between sperm cells’ motor activity and their transitions to hyperactivation phases that may play an important role in fertilization. The finding is part of a larger effort to use math and fluid dynamics to describe how mammalian sperm move. The research is led by a team of engineers at the University of California San Diego. The new work is published in the journal Physical ...
Ochsner Health hospitals and partners earn national recognition from The Leapfrog Group
2023-11-06
NEW ORLEANS, La. – Several Ochsner Health hospitals and partners across the Gulf South have earned an ‘A’ Leapfrog Hospital Safety Grade for Fall 2023.The Leapfrog Group, a national nonprofit watchdog that sets standards for excellence in patient care, assigns a grade to general hospitals across the country based on more than 30 national performance measures reflecting errors, accidents, injuries and infections, as well as the systems hospitals have in place to prevent them.
The following Ochsner Health hospitals and partners received an ...
Neuromorphic computing will be great… if hardware can handle the workload
2023-11-06
Technology is edging closer and closer to the super-speed world of computing with artificial intelligence. But is the world equipped with the proper hardware to be able to handle the workload of new AI technological breakthroughs?
“The brain-inspired codes of the AI revolution are largely being run on conventional silicon computer architectures which were not designed for it,” explains Erica Carlson, 150th Anniversary Professor of Physics and Astronomy at Purdue University.
A joint effort between Physicists from Purdue University, University of California San Diego (USCD) and École ...
Lightening the load: Beckman researchers develop autonomous electrochemistry robot
2023-11-06
Researchers at the Beckman Institute for Advanced Science and Technology developed an automated laboratory robot to run complex electrochemical experiments and analyze data.
With affordability and accessibility in mind, the researchers collaboratively created a benchtop robot that rapidly performs electrochemistry. Aptly named the Electrolab, this instrument greatly reduces the effort and time needed for electrochemical studies by automating many basic and repetitive laboratory tasks.
The Electrolab can be used to explore energy storage materials and chemical reactions that promote the use of alternative ...
Success of Wolbachia-infected mosquitoes in fighting dengue may be underestimated
2023-11-06
The fight against dengue fever has a new weapon: a mosquito infected with the bacteria Wolbachia, which prevents the spread of the virus. These mosquitoes have now been deployed in several trials demonstrating their potential in preventing disease transmission.
Now, researchers at the University of Notre Dame have conducted an analysis of the World Mosquito Program’s randomized control trial of Wolbachia-infected mosquitoes in Indonesia, looking at how excluding transmission dynamics impacted the original interpretation of the trial’s results.
“Randomized controlled trials are the gold standard for evaluating the efficacy of any ...
The uncharted role of HER2 mutant alleles in breast cancer
2023-11-06
“Our research study has demonstrated that poziotinib is highly potent in neratinib-resistant HER2 L755S lobular and ductal breast cancer models [...].”
BUFFALO, NY- November 6, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on October 31, 2023, entitled, “The uncharted role of HER2 mutant alleles in breast cancer.”
Somatic HER2 mutations are a novel class of therapeutic targets across different cancer types. Treatment with the tyrosine kinase inhibitor (TKI) neratinib ...
From basic research to application: NRL geophysicist awarded NDIA Undersea Warfare Bronze Medal Achievement in Science
2023-11-06
WASHINGTON – Warren Wood, Ph.D., U.S. Naval Research Laboratory Ocean Sciences Division’s Geology and Geophysics section head, received the National Defense Industrial Association (NDIA) Bronze Medal on Sept. 19, 2023 during a ceremony held at the Naval Submarine Base in Groton, Conn. for outstanding individual achievement in undersea warfare.
This award-winning work would not have been possible without fantastic teamwork, especially from the staff in Geology and Geophysics and Acoustic Simulation, Measurements & Tactics Branches,” said Wood. “Essentially a software ...
Study highlights optimal timing for assessing orthostatic hypotension in older adults and its impact on fall risk
2023-11-06
A new study, "Timing of Orthostatic Hypotension and its Relationship with Falls in Older Adults", has brought critical insights into the assessment of orthostatic hypotension, a drop in blood pressure commonly found among older adults when transitioning from a sitting or lying position to a standing position that can lead to dizziness and falls.
Published in the Journal of the American Geriatrics Society (JAGS) and based on a secondary analysis of the "Study to Understand Fall Reduction and Vitamin D in You (STURDY)," this study examined the prevalence of orthostatic hypotension at different time points after ...
RIT researcher looks for genetic switch to prevent ‘sleeping sickness’ in cattle
2023-11-06
As parasites adapt to a warming world, an infectious disease expert at Rochester Institute of Technology has his eye on the tsetse fly in sub-Saharan Africa. The biting fly transmits Trypanosomiasis, or “sleeping sickness,” to cattle there and could someday migrate to northern climates, including to the United States.
RIT researcher Bolaji Thomas is leading a $650,000 study funded by the U.S. Department of Agriculture, the National Institute of Food and Agriculture, and the Agriculture ...
Improving the efficacy of cancer immunotherapy with modified CAR-T cells
2023-11-06
CAR-T cell therapy is a last hope for many patients with blood, bone marrow or lymph gland cancer when other treatments such as chemotherapy are unsuccessful. A limiting factor of this otherwise very effective and safe therapy is that the cells used in the process quickly reach a state of exhaustion. Researchers at the University of Freiburg have now been able to prevent this exhaustion and thus significantly improve the effect of the therapy in a preclinical animal model. The new results have been published in the journal Nature Immunology.
Using the body’s own defences ...